T-cell receptor specific for MART-1 peptide-HLA-A*02:01 complex (MART-1 TCR)

The T-cell receptor (TCR) specific for MART-1 peptide-HLA complexes is a specialized immune receptor that recognizes the melanoma-associated antigen MART-1 (also known as Melan-A) when presented by the Human Leukocyte Antigen (HLA) molecule, typically HLA-A*02:01. MART-1 is a differentiation antigen expressed primarily in melanocytes and is highly overexpressed in the majority of cutaneous and uveal melanomas. These TCRs play a critical role in the endogenous immune response against melanoma, and their activation is the primary goal of MART-1-based cancer vaccines. In therapeutic development, high-affinity MART-1-specific TCRs (such as DMF5 and F5) have been cloned and engineered into autologous T cells for adoptive cell therapy (TCR-T), enabling a potent and targeted attack on tumor cells. However, because MART-1 is also expressed in normal melanocytes, therapies targeting this complex can lead to on-target, off-tumor toxicities affecting the skin (vitiligo), eyes (uveitis), and ears (hearing loss). Clinical trials have demonstrated that while these TCR-engineered T cells can induce significant tumor regression, the persistence of the cells and the potential for autoimmune reactions remain significant challenges.

Other names

Melan-A-specific T-cell receptorMART-1-specific TCRTCR specific for Melan-A/MART-1DMF5 TCRF5 TCR1D3 TCR

Agonism of endogenous T-cell receptors via peptide vaccination; Adoptive transfer of T-cells engineered with high-affinity MART-1-specific T-cell receptors to recognize and kill tumor cells.